PMID- 17134062
OWN - NLM
STAT- MEDLINE
DCOM- 20070123
LR  - 20220330
IS  - 1109-9666 (Print)
IS  - 1109-9666 (Linking)
VI  - 47
IP  - 5
DP  - 2006 Sep-Oct
TI  - Clinical and prognostic value of elevated CA125 levels in patients with 
      congestive heart failure.
PG  - 269-74
AB  - BACKGROUND: Increased serum levels of carbohydrate antigen 125 (CA125), a tumor 
      marker associated with ovarian cancer, have also been reported in other malignant 
      and non-malignant diseases. We assessed the correlation of the CA125 serum levels 
      with the severity of congestive heart failure (CHF) and investigated their 
      potential prognostic value in relation to major cardiovascular events. METHODS: 
      CA125 levels were measured in 95 male patients aged 70+/-10 years, admitted for 
      decompensated CHF. The patients were divided into three groups, according to 
      their New York Heart Association (NYHA) functional class. Group A contained 23 
      patients in NYHA IV, group B 34 patients in NYHA III, and group C 38 patients in 
      NYHA I-II. The patients were also divided into two groups according to their 
      CA125 value on admission. Group 1 included 45 patients with normal CA125 levels 
      and group 2 50 patients with elevated CA125. All patients were followed for 
      15+/-8.5 months and the major cardiovascular events (death and 
      re-hospitalizations due to CHF) were recorded. RESULTS: Serum levels of CA125 
      were higher in groups A and B than in group C (36.4 [19.8-82] U/ml and 34.6 
      [26-78] U/ml vs. 25.3 [9.1-29] U/ml, respectively, p<0.05). No correlation was 
      detected between CA125 levels and left ventricular ejection fraction. However, 
      patients with pulmonary congestion and peripheral edemas had higher levels of 
      CA125 (p=0.002 and p<0.03, respectively). Nineteen patients died during the 
      follow-up period, but the mortality rate was not significantly different between 
      groups 1 and 2 (p=0.8). Nevertheless, the patients of group 1 reported fewer 
      re-hospitalizations than patients of group 2 (p=0.003). The relative risk (RR) 
      for re-hospitalization was calculated to be RR: 0.4, 95% CI: 0.215-0.76 
      (p<0.005), in patients with elevated levels of CA125. Cox regression analysis 
      revealed that CA125 had independent prognostic value (OR: 1.007 [95% CI: 
      1.004-1.010], p<0.0001) for re-hospitalizations. CONCLUSION: Serum levels of 
      CA125 are associated with the severity of CHF and are also independent predictive 
      markers for re-hospitalizations. We therefore conclude that CA125 can be used as 
      a prognostic marker of disease severity and increased morbidity in patients with 
      decompensated CHF.
FAU - Kouris, Nikos T
AU  - Kouris NT
AD  - Cardiology department, Western Attica General Hospital, Athens, Greece. 
      nikoskou@otenet.gr
FAU - Kontogianni, Dimitra D
AU  - Kontogianni DD
FAU - Papoulia, Eftihia P
AU  - Papoulia EP
FAU - Goranitou, Georgia S
AU  - Goranitou GS
FAU - Zaharos, Ioannis D
AU  - Zaharos ID
FAU - Grassos, Haris A
AU  - Grassos HA
FAU - Kalkandi, Eleni M
AU  - Kalkandi EM
FAU - Sifaki, Maria D
AU  - Sifaki MD
FAU - Babalis, Dimitris K
AU  - Babalis DK
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Hellenic J Cardiol
JT  - Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese
JID - 101257381
RN  - 0 (Biomarkers)
RN  - 0 (CA-125 Antigen)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - CA-125 Antigen/*blood
MH  - Follow-Up Studies
MH  - Heart Failure/*blood/mortality/physiopathology
MH  - Humans
MH  - Immunoradiometric Assay
MH  - Male
MH  - Prognosis
MH  - Severity of Illness Index
MH  - Stroke Volume
MH  - Survival Rate
EDAT- 2006/12/01 09:00
MHDA- 2007/01/24 09:00
CRDT- 2006/12/01 09:00
PHST- 2006/12/01 09:00 [pubmed]
PHST- 2007/01/24 09:00 [medline]
PHST- 2006/12/01 09:00 [entrez]
PST - ppublish
SO  - Hellenic J Cardiol. 2006 Sep-Oct;47(5):269-74.